Fulcrum Asset Management LLP acquired a new stake in Labcorp Holdings Inc. (NYSE:LH – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,640 shares of the medical research company’s stock, valued at approximately $506,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in Labcorp by 1.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after purchasing an additional 22,170 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Labcorp by 2.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock worth $355,569,000 after acquiring an additional 28,584 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after purchasing an additional 133,549 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Labcorp in the second quarter valued at approximately $168,222,000. Finally, Bessemer Group Inc. boosted its stake in Labcorp by 47.3% in the 1st quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock worth $154,493,000 after purchasing an additional 185,847 shares during the period. Institutional investors own 95.94% of the company’s stock.
Labcorp Price Performance
Shares of LH opened at $370.69 on Monday. The business has a 50-day simple moving average of $329.60 and a two-hundred day simple moving average of $292.58. The stock has a market cap of $30.10 billion, a PE ratio of 30.41, a PEG ratio of 2.09 and a beta of 0.86. Labcorp Holdings Inc. has a 12-month low of $245.00 and a 12-month high of $375.10. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60.
Labcorp (NYSE:LH – Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, topping the consensus estimate of $4.64 by $0.14. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period last year, the company earned $4.18 EPS. Analysts anticipate that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.
Labcorp Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s payout ratio is currently 23.63%.
Analyst Ratings Changes
Several equities analysts have recently weighed in on LH shares. HSBC raised shares of Labcorp from a “hold” rating to a “buy” rating and set a $410.00 price target for the company in a research note on Thursday, November 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $388.00 price target on shares of Labcorp in a report on Thursday, October 29th. Robert W. Baird boosted their price objective on Labcorp from $361.00 to $396.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Piper Sandler upped their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $369.08.
Check Out Our Latest Report on Labcorp
Insider Transactions at Labcorp
In other news, EVP Brian Caveney sold 2,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the sale, the executive vice president directly owned 34,562 shares of the company’s stock, valued at approximately $12,858,446.48. This represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richelle Parham sold 1,078 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $361.22, for a total transaction of $389,395.16. Following the sale, the director directly owned 2,288 shares in the company, valued at $826,471.36. This trade represents a 32.03% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,384 shares of company stock worth $1,241,707. Company insiders own 0.84% of the company’s stock.
Labcorp Profile
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Featured Stories
- Five stocks we like better than Labcorp
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
